Kim Kyung-jin Leads Samyang Biopharma Expansion
Samyang appoints Kim Kyung-jin as biopharma head, focusing on CDMO and mRNA innovation globally.
Samyang Group has announced the appointment of Kim Kyung-jin, the former CEO of ST Pharm, as the president of its biopharma unit. This decision comes as part of the group’s annual personnel reshuffle and strategic organizational restructuring. The move is significant as it follows Samyang's celebration of its 100th anniversary in October, where the company outlined a vision to strengthen its global presence and focus on specialty markets with high-value-added sectors.
Kim brings extensive expertise, having served in prominent roles at Roche and ST Pharm, including as Director of Research and CEO. His background combines deep research experience with strategic leadership, making him well-suited to drive the biopharma unit’s global ambitions.
Under Kim’s leadership, Samyang’s biopharma division plans to expand its contract development and manufacturing organization (CDMO) capabilities. Additionally, the company aims to accelerate research and development efforts, particularly in the field of messenger RNA (mRNA) delivery technologies, aligning with global trends in biopharmaceutical innovation.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein
Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park
Discussion